IAMA Therapeutics Secures $15M Series B to Propel Phase 1 Trials of Its Breakthrough NKCC1 Inhibitor for Rare Epilepsy and Neurodevelopment Disorders

IAMA Therapeutics is thrilled to announce the successful completion of its Series B funding round, raising $15,000,000 to power forward its groundbreaking clinical initiatives. This capital infusion will specifically accelerate the clinical development of IAMA-6, the company’s lead candidate. IAMA-6, a best-in-class selective NKCC1 inhibitor, is being developed to offer a transformative treatment for patients battling epilepsy and various neurodevelopment disorders, including those with drug-resistant epilepsy. The early promise of IAMA-6 is underscored by its entry into Phase 1 clinical trials as of January 2024, marking a pivotal moment in the journey toward offering hope and improved quality of life to patients who have historically faced limited treatment options. Beyond IAMA-6, the company’s robust pipeline also features innovative new molecular entities designed to target Cation Chloride Cotransporters, with the potential to address a range of pediatric neuropsychiatric conditions. This diversified approach not only speaks to IAMA Therapeutics’ commitment to pioneering treatments for orphan brain disorders but also highlights its strategic focus on unmet medical needs within pediatric populations. With the new funding, the company is poised to expand its clinical programs, further engage strategic partners, and forge ahead with a comprehensive research agenda that could redefine therapeutic paradigms in neurology. As IAMA Therapeutics embarks on this next chapter of innovation and growth, the infusion of funds will be instrumental in propelling their mission of delivering transformative solutions to those in need while reshaping the future of neurological care.